What Is Your Skin Cancer IQ?

Publication
Article
OncologyONCOLOGY Vol 21 No 6
Volume 21
Issue 6

May is National Skin Cancer Awareness MonthWhat Is Your Skin Cancer IQ?Identifying BCC, SCC, and melanoma

 
Basal Cell Carcinoma (BCC)
Squamous Cell Carcinoma (SCC)
Melanoma

Appearance

Small, shiny bumps or nodules that are red, pink, or white; persistent, nonhealing sore; reddish flat patch; or a scar-like white or yellowish area
Red, scaly patches or bumps
Asymmetrical, mottled patches with notched or blurred borders, typically in tan, brown, or black
Size
Takes many years or months to reach a half-inch
Can reach up to three-quarters of an inch to an inch
Usually greater than 6 mm
Location
Head, neck, hands, and occasionally on the trunk of the body
Face, ears, neck, lips, and back of the hands
Can occur anywhere on the body, most frequently on the upper back or legs, as well as the head and neck
Progression
Grows slowly and may bleed, crust over, then the cycle repeats
Can develop into large masses
Can appear without warning, or may begin in or near a mole or other dark spot on the skin
Potential for metastasis
Rare, but can grow into nearby areas and may invade bone and vital structures, such as the eye
Can metastasize, and may be fatal if not treated
Can metastasize, and is deadly if not treated
Prevalence
BCC accounts for 80% of all skin cancers (more than 800,000 new cases each year).
SCC accounts for 16% of all skin cancers (approximately 250,000 new cases each year). About 2,500 deaths from SCC are expected during 2007.
Melanoma accounts for 4% of all skin cancers (approximately 59,940 new cases each year). More than 8,110 melanoma deaths are expected during 2007.

Adapted, with permission, from the American Academy of Dermatology’s “Actinic Keratoses and Skin Cancer,” available at http://www.aad.org/public/News/DermInfo/DInfoSkinCancerUpdates.htm.

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Related Content